173 related articles for article (PubMed ID: 20431558)
1. Market watch: emerging companion diagnostics for cancer drugs.
August J
Nat Rev Drug Discov; 2010 May; 9(5):351. PubMed ID: 20431558
[No Abstract] [Full Text] [Related]
2. Impact of genetic diagnostics on drug development strategy.
Million RP
Nat Rev Drug Discov; 2006 Jun; 5(6):459-62. PubMed ID: 16699494
[TBL] [Abstract][Full Text] [Related]
3. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
4. Personalised medicine for cancer: from drug development into clinical practice.
Jain KK
Expert Opin Pharmacother; 2005 Aug; 6(9):1463-76. PubMed ID: 16086635
[TBL] [Abstract][Full Text] [Related]
5. [Molecular diagnosis and therapy in oncology].
Baretton G; Grabbe S; Keilholz U; Sauter G
Onkologie; 2011; 34 Suppl 2():5-9. PubMed ID: 21447986
[No Abstract] [Full Text] [Related]
6. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.
Papadopoulos N; Kinzler KW; Vogelstein B
Nat Biotechnol; 2006 Aug; 24(8):985-95. PubMed ID: 16900147
[TBL] [Abstract][Full Text] [Related]
7. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.
Fridlyand J; Simon RM; Walrath JC; Roach N; Buller R; Schenkein DP; Flaherty KT; Allen JD; Sigal EV; Scher HI
Nat Rev Drug Discov; 2013 Oct; 12(10):743-55. PubMed ID: 24008432
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics and pharmacogenomics as new tools to optimise cancer chemotherapy.
Robert J
J Chemother; 2004 Nov; 16 Suppl 4():22-4. PubMed ID: 15688604
[TBL] [Abstract][Full Text] [Related]
9. Special report: pharmacogenomics of cancer-candidate genes.
Technol Eval Cent Assess Program Exec Summ; 2007 Nov; 22(5):1-3. PubMed ID: 18080403
[No Abstract] [Full Text] [Related]
10. Diagnostics in cancer drug development.
Sikora K
Expert Rev Mol Diagn; 2004 Mar; 4(2):127-9. PubMed ID: 14995899
[No Abstract] [Full Text] [Related]
11. Companion diagnostics.
Becker R; Mansfield E
Clin Adv Hematol Oncol; 2010 Jul; 8(7):478-9. PubMed ID: 20864915
[No Abstract] [Full Text] [Related]
12. Mutation and location important in cancer treatment.
Lewis R
Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321213
[No Abstract] [Full Text] [Related]
13. Personalized cancer therapy gets closer.
Hayden EC
Nature; 2009 Mar; 458(7235):131-2. PubMed ID: 19279593
[No Abstract] [Full Text] [Related]
14. On target. A new generation of drugs offers customized cures.
Fischman J
US News World Rep; 2003 Jan; 134(2):50-2, 55-6, 58. PubMed ID: 12561697
[No Abstract] [Full Text] [Related]
15. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.
Walk EE
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):226-34. PubMed ID: 20205056
[TBL] [Abstract][Full Text] [Related]
16. Challenges for the implementation of routine molecular diagnostics in cancer care.
de Castro DG
Expert Rev Mol Diagn; 2011 Jul; 11(6):549-51. PubMed ID: 21745007
[No Abstract] [Full Text] [Related]
17. Personalized medicine for cancer: from molecular signature to therapeutic choice.
Sikora K
Adv Cancer Res; 2007; 96():345-69. PubMed ID: 17161685
[No Abstract] [Full Text] [Related]
18. Molecular imaging applications in nanomedicine.
Li KC; Pandit SD; Guccione S; Bednarski MD
Biomed Microdevices; 2004 Jun; 6(2):113-6. PubMed ID: 15320632
[TBL] [Abstract][Full Text] [Related]
19. Host pharmacogenetics in the treatment of HIV and cancer.
Winston A; Hatzimichael E; Marvin V; Stebbing J; Bower M
Curr Drug Saf; 2006 Jan; 1(1):107-16. PubMed ID: 18690920
[TBL] [Abstract][Full Text] [Related]
20. Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.
Technol Eval Cent Assess Program Exec Summ; 2011 Nov; 26(7):1-5. PubMed ID: 22724160
[No Abstract] [Full Text] [Related]
[Next] [New Search]
